Baird Medical Expands Global Reach with Argentina Regulatory Clearance
NEW YORK, March 12, 2026 – Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (“Baird Medical” or the “Company”), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced the regulatory clearance of its systems in Argentina. This milestone supports the Company’s international growth and its broader mission to expand patient access to effective, minimally invasive therapies worldwide.
Expanding International Footprint
The Argentine approval adds to Baird Medical’s growing portfolio of international certifications, which already includes clearances from the United States Food and Drug Administration (FDA), Indonesia, Malaysia, and Vietnam. Baird Medical is actively pursuing formal registration in several major regions, with applications currently under review in Egypt, Sri Lanka, the Philippines, Pakistan, and other key international markets. This continued expansion aims to equip healthcare providers globally with advanced tools to address a variety of soft tissue conditions.
About Baird Medical
Baird Medical is a medical device company specializing in minimally invasive diagnostics and treatment. The company focuses on the research and development of surgical robotic systems and innovative surgical instruments. Its mission is to improve patient outcomes through precision technology and advanced diagnostic solutions. Baird Medical intends to foster strategic collaborations with leading academic institutions.
The company’s vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical’s solutions have been utilized in over 30 hospitals and clinics across the United States, including Mayo Clinic, Tulane Medical Center, Columbia University Medical Center, UCSF Medical Center, Weill Cornell Medical Center, and The George Washington University Hospital.
Baird Medical is also the market leader in China for thyroid microwave ablation devices and consumables. Its minimally invasive treatment products are also gaining commercial traction in over 20 countries worldwide.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. These statements relate to future events and Baird Medical’s future financial or operating performance. Terms such as “may,” “could,” “should,” “expect,” “intend,” “might,” “will,” “estimate,” “anticipate,” “believe,” “budget,” “forecast,” “intend,” “plan,” “potential,” “predict,” or “continue” are indicative of forward-looking statements.
These statements are subject to risks, uncertainties, and other factors that could cause actual results to differ materially. These factors include, but are not limited to: the success of expanding business in China or the United States; changes in economic conditions; regulatory changes; legal proceedings; and other risks outlined in the company’s filings with the Securities and Exchange Commission (SEC).
Baird Medical does not undertake any duty to update these forward-looking statements.
Contact Information
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com